U.S. Stock Market Midday Update: Neonc Tech plummets 13.15%, trading volume surges, market volatility draws attention

U.S. Stock Market Midday Update Neonc Tech, down 13.15%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Eli Lilly up 2.70%. Based on recent key news: On December 18, Eli Lilly submitted a new oral weight loss drug orforglipron application to the U.S. FDA. This move may enhance market confidence in its product line, driving the stock price up. On December 18, Eli Lilly announced that its weight loss pill performed well in clinical trials, helping patients maintain weight loss results. Analysts believe this will provide Eli Lilly with opportunities to capture revenue shares from competitor Novo Nordisk, further boosting the stock price. On December 18, Eli Lilly lowered the prices of its diabetes and weight loss drugs in Canada, potentially increasing market competitiveness and attracting more investor attention. The weight loss drug market has significant potential, with noticeable capital inflow. Merck up 1.07%, with a trading volume of $684 million. Based on recent news: On December 18, BMO Capital Markets upgraded Merck's rating to "Outperform," raising the target price from $82 to $130. BMO believes Merck is building a new clinical asset portfolio through external deals and internal R&D assets to address revenue losses after its cancer drug Keytruda loses exclusivity in 2028. This move boosted investor confidence, driving the stock price up. On December 18, Merck announced the results of its Phase III clinical trial of Keytruda combined with Padcev for muscle-invasive bladder cancer, showing significant improvement in progression-free survival. This news further enhanced market expectations for Merck's future growth, pushing the stock price up. On December 19, Merck reached an agreement with the Trump administration to lower drug prices for government programs and cash-paying patients while obtaining several priority review vouchers. This news helps enhance Merck's market competitiveness, promoting stock price growth. The pharmaceutical industry is performing strongly overall, with clear policy support. Johnson & Johnson down 0.96%, with increased trading volume. Based on recent key news: On December 18, Johnson & Johnson's lung cancer drug Rybrevant Faspro received FDA approval. The approval is based on Phase III trial results, showing longer response duration and improvements in progression-free survival and overall survival. This approval may enhance market confidence in Johnson & Johnson's future growth, although the stock price still declined. On December 17, Royal Bank of Canada raised Johnson & Johnson's target price from $230 to $240. Analysts' target price increases typically reflect optimistic expectations for the company's future performance, but Johnson & Johnson's stock price remains under pressure On December 16, Bank of America Securities raised Johnson & Johnson's target price from $204 to $220, maintaining a "Neutral" rating. Despite the target price increase, the rating remains unchanged, indicating a cautious market outlook on Johnson & Johnson. Changes in pharmaceutical industry policies affect stock price volatility. Stocks ranked among the top in industry market capitalization AstraZeneca rose by 1.15%. Based on recent key news: On December 16, AstraZeneca's Saphnelo was approved for the treatment of systemic lupus erythematosus, driving the stock price up. This approval enhances the company's product line in the immunology field and boosts market confidence. On December 17, the FDA approved AstraZeneca's Enhertu in combination with pertuzumab for first-line treatment of breast cancer in collaboration with Daiichi Sankyo. The results of the DESTINY-Breast09 trial showed a significant improvement in progression-free survival, further consolidating AstraZeneca's leading position in oncology treatment. On December 18, AstraZeneca reached an agreement with the U.S. government to provide the most favored nation pricing to reduce drug costs. This initiative aims to align prices with those of other wealthy countries and may have a positive impact on future sales. Changes in global drug pricing policies affect the market